150 Folgen

  1. The End of Transplant for Mantle Cell Lymphoma

    Vom: 31.1.2025
  2. DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

    Vom: 21.12.2024
  3. Haploidentical Stem Cell Transplantation Is an Acceptable Transformative Therapy for Young Adults With Sickle Cell Disease

    Vom: 27.11.2024
  4. Enhancing Risk Stratification for Pediatric B-Cell Acute Lymphoblastic Leukemia: No Longer a ‘PI’ in the Sky Idea?

    Vom: 11.10.2024
  5. A Leap of Faith? Elimination of Autologous Stem Cell Transplantation for Patients With Mantle Cell Lymphoma in First Remission

    Vom: 16.9.2024
  6. Anticoagulation Stewardship

    Vom: 29.8.2024
  7. Blood Global Hematology Editor-in-Chief Shares Vision

    Vom: 17.7.2024
  8. One on One With Dr. Fred Appelbaum

    Vom: 26.6.2024
  9. Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms

    Vom: 21.6.2024
  10. Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

    Vom: 7.5.2024
  11. Growing the Next Generation of Hematologists

    Vom: 15.4.2024
  12. Women in Hematology

    Vom: 26.3.2024
  13. Four Is Better Than Three: Will We Finally Agree?

    Vom: 18.3.2024
  14. Toward Equity in Access for ALL

    Vom: 30.1.2024
  15. The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia

    Vom: 29.11.2023
  16. Editors-in-Chief of Two New ASH Journals Share Their Visions

    Vom: 20.10.2023
  17. ASH’s Minority Recruitment Initiative Mentorship Program Offers a Win for All

    Vom: 18.9.2023
  18. Results From the Blood and Marrow Transplant Trials Network: How Should We Prevent Graft-versus-host Disease in 2023?

    Vom: 1.9.2023
  19. Genetic Background Influences the Growth of CHIP Clones Within the Bone Marrow, With Drs. Robert Hasserjian and Siddhartha Jaiswal

    Vom: 7.7.2023
  20. Drawing New Blood Into Hematology

    Vom: 16.6.2023

1 / 8

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

Visit the podcast's native language site